Unintentional Weight Loss and Cancer: A Prospective Trial of Patient-centered Weight Tracking Combin
Launched by CASE COMPREHENSIVE CANCER CENTER · Jul 28, 2022
Trial Information
Current as of July 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how unintentional weight loss (UWL) can help detect cancer earlier. Unintentional weight loss can happen for various reasons, and researchers are exploring whether tracking this weight loss, along with a special blood test called GRAIL Galleri, can improve our ability to find cancers sooner. Participants in the study will weigh themselves weekly using a smart scale and report their weight changes to help researchers understand the connection between weight loss and cancer detection.
To be eligible for this trial, participants need to be between 40 and 80 years old, have access to a smartphone or computer, and be able to understand and agree to the study's procedures. It's important that they don't currently have cancer or are undergoing treatment for it, and they shouldn't be actively trying to lose weight. During the study, participants will be asked to track their weight regularly and follow any specific instructions given by the research team. This study aims to provide valuable insights that could lead to better ways of identifying cancer at an earlier stage.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age range: from 40 to 80 years
- • Access to a device (cellphone, computer, tablet) that is compatible with the Fitbit Aria Air smart scale utilized in this study
- • Willing to comply with all study procedures and be available for the duration of the study
- • Subjects must be mentally competent and must have the ability to understand and the willingness to sign a written informed consent document
- • Subjects must speak English to maximize chance of understanding the trial rational and study procedures
- Exclusion Criteria:
- • Active cancer diagnosis - current diagnosis, currently undergoing cancer treatment, or concluded cancer treatments within 3 years
- • Actively trying to lose weight with medications or bariatric surgery
- • Pregnant
About Case Comprehensive Cancer Center
Case Comprehensive Cancer Center is a leading academic research institution dedicated to advancing cancer care through innovative clinical trials and cutting-edge research. As a National Cancer Institute-designated Comprehensive Cancer Center, it integrates multidisciplinary approaches to cancer prevention, diagnosis, and treatment, fostering collaboration among clinicians, researchers, and patients. The center is committed to translating scientific discoveries into effective therapies, enhancing patient outcomes, and contributing to the global body of cancer knowledge. With a robust portfolio of clinical trials, Case Comprehensive Cancer Center aims to address the unmet needs of cancer patients and drive progress in the fight against cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cleveland, Ohio, United States
Patients applied
Trial Officials
Jordan M Winter, MD
Principal Investigator
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials